Krystal Biotech (NASDAQ:KRYS) CAO Sells $3,401,750.00 in Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) CAO Kathryn Romano sold 12,500 shares of the stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $272.14, for a total value of $3,401,750.00. Following the completion of the transaction, the chief accounting officer owned 19,318 shares in the company, valued at approximately $5,257,200.52. The trade was a 39.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Krystal Biotech Stock Up 2.3%

NASDAQ KRYS opened at $276.45 on Friday. Krystal Biotech, Inc. has a 52 week low of $122.80 and a 52 week high of $295.98. The business has a 50 day moving average price of $262.06 and a 200-day moving average price of $205.35. The company has a market cap of $8.02 billion, a price-to-earnings ratio of 41.45 and a beta of 0.49.

Institutional Trading of Krystal Biotech

Hedge funds have recently bought and sold shares of the business. FORA Capital LLC bought a new position in Krystal Biotech in the 4th quarter valued at $521,000. Marshall Wace LLP grew its position in Krystal Biotech by 42.5% during the fourth quarter. Marshall Wace LLP now owns 183,754 shares of the company’s stock valued at $45,303,000 after buying an additional 54,794 shares during the period. The Manufacturers Life Insurance Company increased its holdings in Krystal Biotech by 17.9% during the fourth quarter. The Manufacturers Life Insurance Company now owns 40,629 shares of the company’s stock worth $10,056,000 after buying an additional 6,174 shares during the last quarter. CANADA LIFE ASSURANCE Co raised its position in Krystal Biotech by 3.2% in the fourth quarter. CANADA LIFE ASSURANCE Co now owns 22,087 shares of the company’s stock worth $5,446,000 after acquiring an additional 689 shares during the period. Finally, Bridgewater Associates LP boosted its stake in Krystal Biotech by 3.0% in the fourth quarter. Bridgewater Associates LP now owns 10,015 shares of the company’s stock valued at $2,469,000 after acquiring an additional 292 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on KRYS shares. Citigroup upped their target price on shares of Krystal Biotech from $320.00 to $336.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Guggenheim set a $224.00 price objective on Krystal Biotech and gave the stock a “buy” rating in a research note on Friday, October 17th. HC Wainwright reaffirmed a “buy” rating and set a $310.00 target price (up previously from $240.00) on shares of Krystal Biotech in a research report on Friday, January 9th. Weiss Ratings reissued a “hold (c+)” rating on shares of Krystal Biotech in a research report on Monday, December 29th. Finally, Bank of America raised their price objective on Krystal Biotech from $288.00 to $318.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Nine investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $277.89.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.